Literature DB >> 27695174

Acute promyelocytic leukemia after renal transplant and filgrastim treatment for neutropenia.

Jaime A Campbell1, John R Krause1.   

Abstract

Prolonged immunosuppression in solid organ transplant recipients has been considered a risk for developing opportunistic infections and malignancies. Acute leukemia is a rare complication. We report a case of acute promyelocytic leukemia (APL) (FAB M3) after cadaveric renal transplant for focal segmental glomerulosclerosis in a 24-year-old woman. Her immunosuppressive therapy included tacrolimus, mycophenolate mofetil, and prednisone. Approximately 2 years after transplant, she became pancytopenic, prompting administration of filgrastim. A few doses caused a markedly increased blast count, resulting in a diagnosis of APL. She was successfully treated with all-trans-retinoic acid and arsenic trioxide. Myeloproliferative neoplasms after organ transplant or due to filgrastim are rare.

Entities:  

Year:  2016        PMID: 27695174      PMCID: PMC5023296          DOI: 10.1080/08998280.2016.11929484

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  10 in total

Review 1.  Acute promyelocytic leukemia following solid organ transplantation.

Authors:  Armin Rashidi; Paul R Conkling; Stephen I Fisher
Journal:  Ann Hematol       Date:  2015-10-10       Impact factor: 3.673

Review 2.  Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?

Authors:  Ivo P Touw; Marijke Bontenbal
Journal:  J Natl Cancer Inst       Date:  2007-02-07       Impact factor: 13.506

Review 3.  Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature.

Authors:  Farhan Mohammad; Abhirami Vivekanandarajah; Housam Haddad; Christopher M Shutty; Matthew T Hurford; Qun Dai
Journal:  BMJ Case Rep       Date:  2014-05-19

4.  Granulocyte colony-stimulating factor and its receptor in acute promyelocytic leukemia.

Authors:  N Katayama; K Kita; K Kawakami; H Mitani; T Sugawara; S Mizuno; A Yonezawa; K Nishii; H Miwa; H Wada; N Minami; H Shiku
Journal:  Am J Hematol       Date:  1998-05       Impact factor: 10.047

5.  Acute promyelocytic leukemia after living donor partial orthotopic liver transplantation in two Japanese girls.

Authors:  Tomonobu Sato; Ryoji Kobayashi; Akihiro Iguchi; Masahide Nakajima; Saeko Koizumi; Hiroyuki Furukawa; Satoru Todoh; Kunihiko Kobayashi
Journal:  Leuk Lymphoma       Date:  2005-07

Review 6.  Unusual acute promyelocytic leukemia following de novo renal transplant: case report and literature review.

Authors:  C-P Lai; C-C Chang; C-Y Chung; M-L Chen
Journal:  Clin Nephrol       Date:  2011-02       Impact factor: 0.975

7.  Clinical and pathologic features of secondary acute promyelocytic leukemia.

Authors:  Amy S Duffield; Joseph Aoki; Mark Levis; Kathleen Cowan; Christopher D Gocke; Kathleen H Burns; Michael J Borowitz; Milena Vuica-Ross
Journal:  Am J Clin Pathol       Date:  2012-03       Impact factor: 2.493

8.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

Authors:  Philip S Rosenberg; Blanche P Alter; Audrey A Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Carol Fier; Melvin Freedman; George Kannourakis; Sally Kinsey; Beate Schwinzer; Connie Zeidler; Karl Welte; David C Dale
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

9.  The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors.

Authors:  Derwood Pamphilon; Elisabeth Nacheva; Cristina Navarrete; Alejandro Madrigal; John Goldman
Journal:  Transfusion       Date:  2008-03-28       Impact factor: 3.157

10.  Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm.

Authors:  Richard A Larson; Michelle M Le Beau
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.